| Literature DB >> 27788680 |
Alvin Richards-Belle1, Ruth R Canter1, G Sarah Power1, Emily J Robinson1, Henrik Reschreiter2, Hannah Wunsch3, Sheila E Harvey4.
Abstract
BACKGROUND: The present study was designed to (1) establish current sedation practice in UK critical care to inform evidence synthesis and potential future primary research and (2) to compare practice reported via a survey with actual practice assessed in a point prevalence study (PPS).Entities:
Keywords: Analgesia; Critical care; Point prevalence; Sedation; Survey
Mesh:
Substances:
Year: 2016 PMID: 27788680 PMCID: PMC5084331 DOI: 10.1186/s13054-016-1532-x
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
National survey: sedative agents, analgesic agents, sedative/analgesic delivery regimens and their reported frequency of use
| Reported frequency of use, | ||||
|---|---|---|---|---|
| Very frequently/frequently | Occasionally/rarely | Never | Not reported | |
| Sedative agent | ||||
| Propofol | 210 (98.1) | 2 (0.9) | 0 (0) | 2 (0.9) |
| Midazolam | 69 (32.2) | 130 (60.7) | 11 (5.1) | 4 (1.9) |
| Diazepam | 4 (1.9) | 96 (44.9) | 105 (49.1) | 9 (4.2) |
| Lorazepam | 2 (0.9) | 120 (56.1) | 83 (38.8) | 9 (4.2) |
| Clonidine | 70 (32.7) | 129 (60.3) | 8 (3.7) | 7 (3.3) |
| Dexmedetomidine | 22 (10.3) | 57 (26.6) | 127 (59.3) | 8 (3.7) |
| Haloperidol | 79 (36.9) | 115 (53.7) | 13 (6.1) | 7 (3.3) |
| Atypical anti-psychotica | 15 (7.0) | 94 (43.9) | 89 (41.6) | 16 (7.5) |
| Other | 26 (12.1) | 12 (5.6) | – | 176 (82.2) |
| Analgesic agent | ||||
| Morphine | 90 (42.1) | 114 (53.3) | 6 (2.8) | 4 (1.9) |
| Fentanyl | 77 (36.0) | 89 (41.6) | 41 (19.2) | 7 (3.3) |
| Alfentanil | 110 (51.4) | 53 (24.8) | 46 (21.5) | 5 (2.3) |
| Remifentanil | 72 (33.6) | 106 (49.5) | 32 (15.0) | 4 (1.9) |
| Ketamine | 1 (0.5) | 177 (82.7) | 28 (13.1) | 8 (3.7) |
| Other | 3 (1.4) | 9 (4.2) | – | 202 (94.4) |
| Sedative/analgesic delivery regimen | ||||
| Single sedative agent | 47 (22.0) | 142 (66.4) | 4 (1.9) | 21 (9.8) |
| Sedative(s) in combination with one or more analgesic agents | 207 (96.7) | 4 (1.9) | 0 (0) | 3 (1.4) |
| Multiple sedatives together | 23 (10.8) | 163 (76.2) | 5 (2.3) | 23 (10.7) |
a For sedative purposes only
Point prevalence study: sedative and analgesic agents received
| Received | Highest rate of infusion (mg/h) | Total dose (mg) | |||
|---|---|---|---|---|---|
|
| Reported, | Mean (SD)a | Reported, | Mean (SD)a | |
| Sedative agent | |||||
| Propofol | 174 (71.9) | 162 | 138 (87) | 172 | 2052 (1734) |
| Haloperidol | 8 (3.3) | 1 | – | 8 | 6.6 (3.8) |
| Midazolam | 21 (8.7) | 16 | 7.1 (4.8) | 21 | 97.2 (121.5) |
| Clonidine | 20 (8.3) | 9 | 0.17 (0.18) | 18 | 1.3 (1.9) |
| Dexmedetomidine | 4 (1.7) | 3 | – | 3 | – |
| Ketamine | 1 (0.4) | 1 | – | 1 | – |
| Diazepam | 4 (1.7) | 0 | – | 4 | – |
| Lorazepam | 3 (1.2) | 0 | – | 2 | – |
| Olanzapine | 2 (0.8) | 0 | – | 1 | – |
| Thiopentone | 2 (0.8) | 0 | – | 2 | – |
| Analgesic agent | |||||
| Alfentanil | 76 (31.4) | 74 | 2.3 (1.9) | 76 | 40.9 (36.6) |
| Fentanyl | 66 (27.3) | 59 | 0.15 (0.21) | 59 | 1.7 (1.5) |
| Remifentanil | 24 (9.9) | 22 | 0.57 (0.63) | 21 | 9.3 (9.6) |
| Morphine | 48 (19.8) | 20 | 4.3 (4.5) | 46 | 57.8 (83.8) |
a Included only if reported for at least five patients
Point prevalence study: most frequent combinations of sedative and analgesic agents and single sedative/analgesic agents
| Sedative/analgesic agents |
|
|---|---|
| Most frequenta combinations of sedative and analgesicb agents | |
| Propofol and alfentanil | 49 (20.3) |
| Propofol and fentanyl | 44 (18.2) |
| Propofol and remifentanil | 12 (5.0) |
| Propofol and morphine | 10 (4.1) |
| Propofol, midazolam and alfentanil | 4 (1.7) |
| Propofol, midazolam and fentanyl | 4 (1.7) |
| Propofol, clonidine and alfentanil | 3 (1.2) |
| Most frequenta single sedative agents | |
| Propofol | 15 (6.2) |
| Clonidine | 5 (2.1) |
| Most frequenta single analgesicb agents | |
| Morphine | 22 (9.1) |
| Fentanyl | 8 (3.3) |
| Alfentanil | 5 (2.1) |
| Remifentanil | 4 (1.7) |
a Combinations/single agents included only if reported for at least three patients
b With or without additional paracetamol, codeine or bupivacaine
Reported versus actual sedation scale/score use
| Point prevalence study | Sedation scale/score reported in national survey | ||
|---|---|---|---|
| Richmond Agitation-Sedation Scale | Ramsay Sedation Scale | Riker Sedation-Agitation Scale | |
| Patients who received any sedative/analgesic agenta, | 149 | 56 | 12 |
| Sedation scale/score used, | |||
| Assessed with reported scale/score | 114 (76.5) | 27 (48.2) | 11 (91.7) |
| Assessed with different scale/score | 26 (17.4) | 10 (17.9) | 0 (0) |
| Not assessed with a scale/score | 9 (6.0) | 19 (33.9) | 1 (8.3) |
| Percentage of patients assessed with reported scale/score across unitsb, median (IQR) | 88 (63–100) | ||
a Sedated patients in units that participated in the point prevalence study and reported using the indicated sedation scale/score
b Excluding units with fewer than three eligible patients (n = 20)
Reported versus actual sedative and analgesic agent use
| Point prevalence study | First-choice sedative agent reported in national survey | |||
| Propofol | Midazolam | |||
| Patients who received any sedative agenta, | 170 | 18 | ||
| Patients who received unit’s first-choice sedative agent, | 149 (87.6) | 6 (33.3) | ||
| Percentage of patients who received first-choice sedative across unitsb, median (IQR) | 100 (64–100) | |||
| Point prevalence study | First-choice analgesic agent reported in national surveyc | |||
| Alfentanil | Fentanyl | Remifentanil | Morphine | |
| Patients who received any analgesic agentd, | 75 | 61 | 22 | 28 |
| Patients who received unit’s first-choice analgesic agent, | 58 (77.3) | 57 (93.4) | 12 (54.5) | 15 (53.4) |
| Percentage of patients who received first-choice analgesic across unitse, median (IQR) | 80 (67–100) | |||
a In critical care units reporting in the national survey that they use the indicated sedative agent as their first choice
b Excluding units with fewer than three eligible patients (n = 23)
c Ten patients in two units that reported using two alternative analgesic agents as their first choice are excluded from data for individual agents but included in summary data across units (where either of the two indicated agents may have been used)
d In critical care units reporting in the national survey that they use the indicated analgesic agent as their first choice
e Excluding units with fewer than three eligible patients (n = 19)